文献速递神经肿瘤

非典型和恶性脑膜瘤根治性治疗后的复发组织病理学预后因素

Histopathological prognostic factors of recurrence following definitive therapy for atypical and malignant meningiomas.
PubMed 文献 · J Neurosurg · 2017-06-16

该回顾性研究纳入2007至2014年按WHO 2007标准诊断并接受手术联合外照射放疗的76例WHO II级和III级脑膜瘤患者,中位随访52.6个月,发现III级组织学、脑和/或骨侵犯及Ki-67增殖指数≥3%可预测进展/复发,并据此进行风险分层。

要点

  • III级组织学、脑和/或骨侵犯、Ki-67≥3%为进展/复发的预测因素。
  • III级组织学患者粗进展/复发率为80%,脑和/或骨侵犯者为40%,增殖指数≥3%者为20%。
  • 治疗失败者中位增殖指数为11%,未失败者为1%,两者差异显著。

核心结论

  • 在非典型或恶性脑膜瘤患者中,III级组织学、脑和/或骨侵犯及高核分裂指数显著预测联合治疗后的治疗失败风险增加。
  • 这些患者可分层为预测进展/复发的风险组。
  • 具有高风险特征的患者可能从比目前常规提供的更多治疗和咨询中获益。

研究设计与样本

  • 回顾性研究,纳入2007年至2014年按WHO 2007标准诊断的WHO II级和III级脑膜瘤患者,均接受手术和外照射放疗,共76例(66例II级,10例III级)。
  • 从病理诊断起中位随访52.6个月。

主要发现

  • III级组织学患者粗进展/复发率为80%。
  • 脑和/或骨侵犯者(不论WHO分级)粗进展/复发率为40%。
  • 增殖指数≥3%者(不论WHO分级)粗进展/复发率为20%。
  • 治疗失败者中位增殖指数为11%,未失败者为1%,两者差异显著。

关键数值与推荐

  • III级组织学预测进展/复发。
  • 脑和/或骨侵犯预测进展/复发。
  • Ki-67增殖率≥3%预测进展/复发。

临床怎么用

  • 原文未据此给出具体推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE Patients with atypical and malignant (WHO Grade II and III) meningiomas have a worse prognosis than patients with benign (WHO Grade I) meningiomas. However, there is limited understanding of the pathological risk factors that affect long-term tumor control following combined treatment with surgery and radiation therapy. Here, the authors identify clinical and histopathological risk factors for the progression and/or recurrence (P/R) of high-grade meningiomas based on the largest series of patients with atypical and malignant meningiomas, as defined by the 2007 WHO classification. METHODS Patients diagnosed with WHO Grade II and III meningiomas between 2007 and 2014 per the WHO 2007 criteria and treated with both surgery and external beam radiation therapy were retrospectively reviewed for clinical and histopathological factors at the time of diagnosis and assessed for P/R outcomes at the last available follow-up. RESULTS A total of 76 patients met the inclusion criteria (66 Grade II meningiomas, 10 Grade III meningiomas). Median follow-up from the time of pathological diagnosis was 52.6 months. Three factors were found to predict P/R: Grade III histology, brain and/or bone invasion, and a Ki-67 proliferation rate at or above 3%. The crude P/R rate was 80% for patients with Grade III histology, 40% for those with brain and/or bone involvement (regardless of WHO tumor grade), and 20% for those with a proliferative index ≥ 3% (regardless of WHO tumor grade). The median proliferation index was significantly different between patients in whom treatment failed and those in whom it did not fail (11% and 1%, respectively). CONCLUSIONS In patients with atypical or malignant meningiomas, the presence of Grade III histology, brain and/or bone involvement, and a high mitotic index significantly predicted an increased risk of treatment failure despite combination therapy. These patients can be stratified into risk groups predicting P/R. Patients with high-risk features may benefit from more treatment and counseling than is typically offered currently.

来源:J Neurosurg,查看原文。版权归原作者所有。

引用

  1. Kim D, Niemierko A, Hwang WL, et al. Histopathological prognostic factors of recurrence following definitive therapy for atypical and malignant meningiomas. J Neurosurg. 2017. PMID: 28621619. doi:10.3171/2016.11.JNS16913

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。